Carlsmed, Inc. (CARL)
NASDAQ: CARL · Real-Time Price · USD
14.78
+0.36 (2.50%)
At close: Oct 12, 2026, 4:00 PM EDT
14.71
-0.07 (-0.47%)
After-hours: Oct 12, 2026, 4:28 PM EDT
Company Description
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions.
The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures.
Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants.
The company was incorporated in 2018 and is based in Carlsbad, California.
Carlsmed, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 23, 2025 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 127 |
| CEO | Michael Cordonnier |
Contact Details
Address: 1800 Aston Avenue, Suite 100 Carlsbad, California 92008 United States | |
| Phone | 760 766 1923 |
| Website | carlsmed.com |
Stock Details
| Ticker Symbol | CARL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 1794546 |
| CUSIP Number | 14280C105 |
| ISIN Number | US14280C1053 |
| Employer ID | 83-1081863 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Michael John Cordonnier | Co-Founder, Chairman, Chief Executive Officer and President |
| Niall Patrick Casey J.D. | Co-Founder, Chief Intellectual Property Officer and Director |
| Leonard M. Greenstein J.D. | Chief Financial Officer and Treasurer |
| William Durall | Chief Commercial Officer |
| Jeff Bertolini | Chief Operating Officer |
| Shariq Hussain | Chief Technology Officer |
| Stephanie Zhadkevich | Vice President and Head of Investor Relations |
| Jenifer Kamocsay | Chief Legal Officer and Secretary |
| Jodi Allen Coe M.B.A. | Senior Vice President of People and Culture |
| Sharon V. Schulzki | Chief Clinical and Market Access Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 5, 2026 | 144 | Filing |
| Oct 1, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 30, 2026 | 144 | Filing |
| Sep 30, 2026 | 8-K | Current Report |
| Sep 8, 2026 | 8-K | Current Report |
| Aug 21, 2026 | EFFECT | Notice of Effectiveness |
| Aug 14, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 5, 2026 | 10-Q | Quarterly Report |
| Aug 5, 2026 | 8-K | Current Report |
| Jun 3, 2026 | 8-K | Current Report |